BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 6794578)

  • 1. General pharmacological properties of UFT, a new type of anti-cancer agent consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and uracil. I: Pharmacological analysis of the combined effect of FT and uracil.
    Yamamoto J; Toide K; Haruno A; Yoshimura Y; Unemi N
    Arzneimittelforschung; 1981; 31(8):1268-78. PubMed ID: 6794578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
    Shirasaka T; Shimamoto Y; Kato T; Fukushima M
    Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
    Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
    Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
    Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
    Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
    Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
    Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General pharmacological studies on N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate. 1st communication: effect on the central nervous system.
    Hirotsu I; Kihara T; Nakamura S; Hattori Y; Hatta M; Kitakaze Y; Takahama K; Hashimoto Y; Miyata T; Ishihara T
    Arzneimittelforschung; 1988 Oct; 38(10):1398-409. PubMed ID: 3196380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
    Tomita T; Tajima T; Ishibashi M; Tagaya N; Aoki H; Itoh S; Kadowaki A; Kogure H; Tajima Y
    Gan To Kagaku Ryoho; 1989 Dec; 16(12):3755-62. PubMed ID: 2512859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a fluorinated pyrimidinedione anti-cancer drug, 5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FT), and related compounds on nigro-striatal dopaminergic neurons in the central nervous system.
    Toide K; Unemi N; Segawa T
    Arch Int Pharmacodyn Ther; 1985 Mar; 274(1):111-24. PubMed ID: 3925907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antineoplastic effect of UFT therapy (uracil-FT-207 combination therapy) on experimental pancreatic cancer transplanted in the pancreas and subcutaneous region].
    Ohyama K; Koike D; Odake Y; Takiyama Y; Saitoh T; Kagaya T; Takebe T; Ishii K
    Gan To Kagaku Ryoho; 1982 Dec; 9(12):2168-74. PubMed ID: 6307180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Studies on the mechanism of antitumor activity of 5-FU and its derivatives--relationship between the inhibition of tumor growth and the inhibition of thymidylate synthetase in vivo].
    Nakamura H; Yu-Qin W; Miyauchi S; Nishioka N; Tanaka H; Harada N; Shirasaka T; Fujii S
    Gan To Kagaku Ryoho; 1984 May; 11(5):1049-55. PubMed ID: 6426401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General pharmacology of the new quinolone antibacterial agent levofloxacin.
    Takasuna K; Kasai Y; Usui C; Takahashi M; Hirohashi M; Tamura K; Takayama S
    Arzneimittelforschung; 1992 Mar; 43(3A):408-18. PubMed ID: 1622443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 2: General pharmacological properties.
    Zwagemakers JM; Claassen V
    Arzneimittelforschung; 1980; 30(9):1526-34. PubMed ID: 7193021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between the anti-metastatic effect of UFT and in vitro chemosensitivity to 5-FU in metastatic tumors from orthotopic implanted colon cancer in nude rats].
    Ogata Y; Akagi Y; Nozoe Y; Sasatomi T; Miyagi Y; Nakagawa M; Matono K; Kobayashi H; Shirouzu K
    Gan To Kagaku Ryoho; 2001 May; 28(5):655-60. PubMed ID: 11383214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological studies on timiperone, a new neuroleptic drug Part II: General pharmacological properties.
    Yamasaki T; Kojima H; Tanaka M; Aibara S; Hirohashi M; Kasai Y; Tsubokawa M; Watanabe K; Akashi A
    Arzneimittelforschung; 1981; 31(4):707-15. PubMed ID: 6113834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dipyridamole augments the antitumor effects of fluorinated pyrimidines.
    Sakaguchi Y; Kusumoto T; Kusumoto H; Maehara Y; Furusawa M; Sugimachi K
    Anticancer Res; 1992; 12(1):119-21. PubMed ID: 1567156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.